Navigation Links
Cystinosis in Medical News

Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of del...

2009 Science Report on Genetic Disease Released by Cystinosis Research Foundation

Researchers of the genetic disease Cystinosis report encouraging news. The Cystinosis Research Foundation has published the third edition of its Science Report, which is designed to provide updates on cystinosis research under way and includes new abstracts of the 12 cystinosis grants issued in 2...

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement

...t populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis , non-alcoholic steatohepatitis ("NASH") , Huntington's Disease ("HD") , and aldehyde dehydrogenase ("ALDH2") deficiency . Raptor's ...

Cystinosis Research Network Unveils New Communication Strategy and Website

... cystinosis Research Network, a non-profit organization fundin... Lake Forest, IL (PRWEB) January 29, 2009 -- The cystinosis Research Network, a non-profit organization aimed ...ve the organization's efficacy as the voice of the cystinosis community. President and Executive Director Ch...
Cystinosis in Medical Technology

Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

...se Cysteamine ("DR Cysteamine") for the potential treatment of nephropathic cystinosis ("cystinosis"), non-alcoholic steatohepatitis ("NASH") and Huntington's Dis... Company expects to conduct its pivotal clinical study for DR Cysteamine in cystinosis in the second half of 2009 and file an NDA in 2010. In February, 2009...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

...ration ("FDA") and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), has demonstrated potential efficacy in preclinical and clin...ategy is to leverage cysteamine's known safety profile for the treatment of cystinosis and potential efficacy in several other indications. In this case, cysteami...

Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program

... the greatest potential impact. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting plat...

Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease

...an Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare, genetic lysosomal storage ...ns to initiate a pivotal study of DR Cysteamine in cystinosis patients in 2009. About Raptor Pharmaceuticals C...e dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor...

Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)

...ration ("FDA") and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare and genetic lysosomal storage disease. Raptor is dev...ments: Raptor's ability to develop DR Cysteamine for the treatment of NASH, cystinosis and other indications; Raptor's ability to formulate and manufacture DR Cys...

Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease

...tly involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from ...
Cystinosis in Medical Definition

Pathology

... , Propionic acidemia , Methylmalonic acidemia , Isovaleric acidemia , 3-Methylcrotonyl-CoA carboxylase deficiency ) - Transport ( Cystinuria , cystinosis , Hartnup disease ) - Sulfur ( Homocystinuria , Cystathioninuria ) - Urea cycle ( Argininosuccinic aciduria , Citrullinemia , Hyperammonemia...
Cystinosis in Medical Dictionary

Cystinosis

Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of the amino acid cystine. It is a genetic disorder that typically follows an autosomal recessive inheritance pattern. Cystinosis is the... Cystinosis Foundation was founded in 1983 and is an all ...
Cystinosis in Biological News

Brain-nourishing molecule may predict schizophrenia relapse

...clear. Exercise can increase BDNF levels. Two drugs currently on the market for other medical conditions erythropoietin for anemia and cysteamine for cystinosis can as well. Dr. Pillai hopes his laboratory studies of these drugs will soon result in an adjunct therapy that can help patients avoid devastating r...
Cystinosis in Biological Technology

Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008

Cystinosis Foundation Ireland to Host Event June 27-28, 2008 NOVATO, Calif., June 23 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Ted Daley, President of Raptor's clinical division, will present at the...

Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis

NOVATO, Calif., June 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD...

Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)

...expect FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. For ...LDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bi...

Raptor Pharmaceuticals Closes $10 Million Private Placement

... approval and commercialization. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(...

Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention

...r currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and NASH. For additional information, please visit http://www.raptorpharma.com . FORWARD LOOKING STATEMENTS This document contains forward-l...

Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease

...r currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and NASH. For additional information, please visit http://www.raptorpharma.com . FORWARD LOOKING STATEMENTS This docum...

Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline

...teamine is currently approved by the FDA for the management of nephropathic cystinosis ("cystinosis"), a genetic lysosomal storage disease characterized by the po...al rights to Cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases. In addition to our ongoing clinical trial i...

Raptor Pharmaceuticals Acquires Orphan Clinical Program

...ay in a clinical trial generously supported by the cystinosis Research Foundation of Irvine, CA. The active ingr...ain the lead clinical investigator for the ongoing cystinosis trial. "Although cysteamine bitartrate has been ... "Through the generous and untiring support of the cystinosis Research Foundation over the past five years, we h...
Other Tags
(Date:7/31/2015)... ... July 31, 2015 , ... India Network Foundation sponsors visitor health ... or family visit for the past 25 years. As India Network offers coverage for ... travel and spend time with their children and grand children. India Network specializes ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... , ... In an effort to provide the twenty four hour continuous care ... his practice. , The decision will also allow him to spend more time in ... his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always ...
(Date:7/30/2015)... ... 2015 , ... Eyepartner is proud to highlight that their ... Gaslamp Quarter Plaza for five years this September. , The surveillance and ... any suspicious activity. These cameras are in place to provide inarguable proof in ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
Other Contents